Delivered mechanistic PoC in cirrhosis/HE Ph1b
Completed enrolment in n=122 Ph2 IBS trial. Delivered safety & efficacy data from IBS-C cohort
Delivering Ph2 trial in allo-HSCT in collaboration with Imperial College
Available data suggests that drug has robust safety and tolerability profile
Proprietary stabilising technology demonstrated 12 months of stability at ambient temperature

Clinical pipeline